Recommendation of the President – Keytruda (pembrolizumab)
On 5 February 2026, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 16/2026 on the reimbursement of the medicinal product Keytruda (pembrolizumab) under the drug program: B.58. “Treatment of patients with esophageal, gastroesophageal junction, and stomach cancer (ICD-10: C15-C16)”